肠促胰岛素相关药物的不良反应

摘要

胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂是已获准用于2型糖尿病治疗的肠促胰岛素相关药物。但因此类药物的使用时间尚短，故其安全性仍受到广泛关注。本文概要介绍肠促胰岛素相关药物的不良反应。%ABSTRACT Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are two kinds of incretin-related agents permitted to be used for the type 2 diabetes treatment. However, in consideration of the application of short time, the extensive attention should be paid to their safety. This review outlines the adverse reactions of these agents.